Mesenchymal stromal cells for immunoregulation after liver transplantation: the scene in 2016.
Curr Opin Organ Transplant
; 21(6): 541-549, 2016 Dec.
Article
em En
| MEDLINE
| ID: mdl-27750256
ABSTRACT
PURPOSE OF REVIEW The current review presents an update on the existing preclinical and human experience of mesenchymal stromal cell (MSC) therapies for post-transplant immunomodulation. RECENT FINDINGS:
Although results from early clinical studies have demonstrated that the application of autologous and allogeneic MSC to be both safe and feasible in a solid organ transplantation setting, for example in liver, the efficacy of MSC immunotherapy demonstrated in preclinical models has yet to be replicated in human clinical trials.SUMMARY:
Eagerly awaited results from the second generation of solid organ transplantation clinical trials, many of which are nearing completion, will perhaps establish the effectiveness of combining MSCs and low-dose pharmacological immunosuppression in promoting graft acceptance. At present, the question of whether infusional cell products based on MSCs will have a significant clinical impact in the field of liver transplantation remains open.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Transplante de Fígado
/
Transplante de Células-Tronco Mesenquimais
/
Imunomodulação
Tipo de estudo:
Prognostic_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article